Denali Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DNLI research report →
Range $26 – $41
Price Chart
About the company
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc.
- CEO
- Ryan J. Watts
- IPO
- 2017
- Employees
- 503
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on DNLI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.96B
- P/E
- -10.40
- PEG
- -0.25
- P/S
- 134.94
- P/B
- 3.66
- EV/EBITDA
- -10.04
- Div Yield
- 0.00%
- Gross Margin
- 71.96%
- Op Margin
- -2488.14%
- Net Margin
- -1470.50%
- ROE
- -33.98%
- ROIC
- -45.42%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-11,183,000+0.0%
- Op Income
- $-555,342,000
- Net Income
- $-512,540,000-21.2%
- EPS
- $-2.97-15.6%
- OCF Growth
- -18.7%
- FCF Growth
- -16.1%
- 52W High
- $27.30
- 52W Low
- $15.34
- 50D MA
- $19.48
- 200D MA
- $21.15
- Beta
- 1.08
- RSI (14)
- 44
- Avg Volume
- 1.64M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Denali delivered a much stronger-than-expected AVLAYAH launch, while also nearing key 2027 clinical and regulatory milestones across its pipeline.· November 3, 2026
- AVLAYAH net product revenue was $17.8 million in Q3, up almost fivefold from $3.6 million in its first full commercial quarter and above prior guidance of $10 million to $12 million.
- Fourth-quarter AVLAYAH revenue guidance was raised to $30 million to $32 million, supported by faster-than-expected uptake, broader payer coverage, and a new J-code effective October 1.
- Commercial coverage for AVLAYAH rose from more than 50% to more than 70% of commercial lives, and 20 state Medicaid programs now list it as covered.
- The Sanfilippo program completed the prespecified treatment duration for the primary endpoint; Denali still plans a BLA filing in 2027 and an accelerated-approval path.
- Both Alzheimer’s programs are now in the clinic, with initial data expected in 2027; Denali also said 2027 will bring readouts from five TransportVehicle programs.
Denali reported AVLAYAH net product revenue of $17.8 million in Q3 2026 and $21.4 million year-to-date. Revenue was up almost fivefold from $3.6 million in the first full commercial quarter and came in well above the $10 million to $12 million guided in August. The company guided Q4 AVLAYAH net product revenue to $30 million to $32 million. Operating expenses in Q3 and year-to-date were essentially flat versus last year despite launch and pipeline spending. Net income was $70.1 million, primarily due to one-time gross proceeds of $195 million from the sale of the PRV. Denali ended September with approximately $1.01 billion in cash, cash equivalents and marketable securities.
Ryan Watts framed the quarter as a turning point, calling it a “defining quarter” and emphasizing that AVLAYAH is the first FDA-approved therapy of its kind for Hunter syndrome and the first commercial proof point for the TransportVehicle platform. He highlighted a broad pipeline behind the launch, with Sanfilippo, FTD granulin, Pompe, and two Alzheimer’s programs all moving toward major readouts. His tone was upbeat but disciplined, repeatedly stressing that the launch is ahead of plan while warning that the recent revenue step-up should not be treated as a run rate.
Alexander Schuth focused on execution, capital efficiency, and balance sheet strength. He said operating expenses were essentially flat year over year in Q3 and year-to-date despite the AVLAYAH launch, and noted the company’s $1.01 billion in cash, cash equivalents and marketable securities at quarter-end. He also tied that balance sheet to Denali’s ability to fund its D3x3 goals through 2028 and to advance the portfolio without near-term financing pressure.
Most of the Q&A centered on how much of AVLAYAH’s Q4 step-up comes from the new J-code, broader coverage, and the faster-than-expected move of Phase I/II patients onto commercial therapy. Management said the J-code should make reimbursement smoother, but emphasized that revenue is the best launch metric and that patient-by-patient metrics are still moving. On Sanfilippo, management reiterated that the BLA package will use data from all 20 patients and that timing is driven by Module 3/manufacturing readiness. On Alzheimer’s and FTD, management stressed that the bar is a believable, robust biomarker response, with dose selection for DNL628 driven by CSF tau and FTD granulin focusing on NfL after the program’s endpoint was extended to 1 year.
The call showed clear commercial traction for AVLAYAH, with revenue well ahead of plan, access expanding quickly, and management saying the launch is ahead of expectations. Denali also has multiple 2027 catalysts queued up across Sanfilippo, FTD granulin, Pompe, and both Alzheimer’s programs, while keeping a large cash balance and essentially flat operating expenses.
Management repeatedly cautioned that the recent AVLAYAH revenue jump is not a steady-state run rate, and that launch metrics like patients on therapy are still evolving. The Sanfilippo BLA timing depends on manufacturing readiness, and for the Alzheimer’s programs and FTD granulin, the company has not yet defined the exact biomarker thresholds that would justify moving forward.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.7%
- Shares Outstanding
- 160.29M
- Float Shares
- 150.13M
of shares held by institutions
303 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19.62M | ▲ 3.44M |
| Blackrock, Inc. | 14.33M | ▲ 302.27K |
| Vanguard Group Inc | 13.06M | ▲ 1.06M |
| Baillie Gifford & Co | 11.12M | ▼ 840.28K |
| Temasek Holdings (Private) Ltd | 7.01M | 0 |
| Vanguard Portfolio Management LLC | 6.76M | ▲ 281.35K |
| Vanguard Capital Management LLC | 6.75M | ▲ 475.50K |
| State Street Corp | 6.68M | ▼ 367.29K |
| Fmr LLC | 4.53M | ▼ 2.71K |
| Geode Capital Management, LLC | 4.04M | ▲ 65.48K |
| Goldman Sachs Group Inc | 3.75M | ▼ 401.31K |
| Baker Bros. Advisors LP | 3.73M | 0 |
Held by 358 ETFs
Biggest fund positions in DNLI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Schuth Alexander O. | other | 16,566 |
| Nov 17, 26 | Schuth Alexander O. | other | 16,566 |
| Sep 4, 26 | Chin Peter Scott | sell | 1,654 |
| Sep 2, 26 | Thornberry Nancy | sell | 10,824 |
| Sep 2, 26 | Thornberry Nancy | sell | 615 |
| Sep 1, 26 | Schuth Alexander O. | sell | 2,768 |
| Aug 12, 26 | Watts Ryan J. | other | 32,220 |
| Aug 11, 26 | Schuth Alexander O. | sell | 2,857 |
| Jun 3, 26 | FLATLEY JAY T | other | 6,408 |
| Jun 3, 26 | FLATLEY JAY T | other | 19,226 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DNLI coverage
Recent articles, reports, and earnings notes.
No research on DNLI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DNLI report →Denali Therapeutics Inc. (DNLI) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Aberdeen Group plc Buys 175,124 Shares of Denali Therapeutics Inc. $DNLI
defenseworld.net · Nov 17
Denali Therapeutics Inc. $DNLI Position Boosted by Fisher Asset Management LLC
defenseworld.net · Nov 15
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 13
Denali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)
seekingalpha.com · Nov 13
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
marketbeat.com · Nov 13
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
zacks.com · Nov 5
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.